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Osteopetrosis is a rare bone disease characterized by an
abnormal increase in bone density and a decrease in bone
mechanical strength, and comprises a heterogeneous group
of disorders.1 Autosomal recessive osteopetrosis (ARO) is
the most severe form of osteopetrosis, with the most* Corresponding author. Department of Medical Genetics, China
Medical University Hospital, Number 2, Yude Road, 404, Taichung,
Taiwan.
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1875-9572/Copyright ª 2016, Taiwan Pediatric Association. Published bsevere symptom being the lack of bone marrow. An
abnormal inward expansion of bone cortex interferes with
normal medullary hematopoiesis and causes life-
threatening pancytopenia and infection.1
Several gene mutations are associated with malignant
infantile ARO.2 Because osteopetrosis-associated trans-
membrane protein-1 (OSTM1), T-cell, immune regulator 1,
ATPase, Hþ transporting, lysosomal V0 subunit A3 (TCIRG1),
and chloride channel-7 protein (CLCN7) mutations account
for at least 60% of malignant infantile ARO cases, we
selected these genes as the targets of our investigation.3
Here we report a unique CLCN7 gene mutation in a Taiwa-
nese patient with malignant infantile ARO.y Elsevier Taiwan LLC. All rights reserved.
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The patient in this study was a boy, aged 2 years and 9
months. He was the second child born to non-
consanguineous, healthy Taiwanese parents, and had two
healthy sisters. At 2-months old, his parents noticed poor
feeding habits and frequent, irritable crying, however, his
general practitioners did not identify any health problems.
At 3-months old, he was taken to a local hospital because of
his pale appearance and noticeable visceromegaly and
diagnosed with thrombocytopenia, borderline anemia, and
hepatosplenomegaly, involving the following blood cell
counts: white blood cell count, 9200/mL; neutrophil/
lymphocyte, 42%/51%; hemoglobin (Hb), 9.2 gm/dL; and
platelets, 13,100/mL. A follow-up visit at 5-months old
revealed a “failure to thrive” and a developmental delay,
which included a head lag while pulling to sit, poor head
control, and poor coordination when sucking, swallowing,
and breathing. At 7-months of age, a brain computed to-
mography scan was performed on the patient because of
repeated projectile vomiting episodes. The images showed
enlargement of brain ventricles, a bulging anterior fonta-
nelle, and diffuse brain atrophy that required a subsequent
ventriculoperitoneal shunt to relieve increased intracranial
pressure. He was referred to China Medical University
Hospital at 2-years-7-months of age because of a continu-
ously worsening pale appearance and an exaggerated
abnormal blood profile. At that time, blood work showed
life-threatening anemia (Hb, 3.2 gm/dL; mean corpuscular
volume, 94.2 fL; reticulocyte count, 15.56%) and theFigure 1 Images of the patient at 2-years-9-months of age. (A) Lo
film. (B) Radiographic evidence of a left humerus fracture. (C) Asym
a bulging mass over the right parietal area of the scalp disclosingperipheral blood smear test showed leukoerythroblastosis.
Aspiration of patient bone marrow was attempted, how-
ever, it failed because the patient’s bone was too “hard” to
allow access to the bone marrow cavity. A skeletal radio-
graphic survey revealed a typical “bone within bone” image
and a fractured left humerus (Figure 1). Combined with the
other clinical data, ARO was the final diagnosis.
Informed consent was obtained from the parents of the
patient to perform a series of genetic analyses. The
detailed methods are described in Supplementary Material.
3. Results and discussion
The early onset of patient clinical manifestations and the
mode of inheritance were highly compatible with malignant
infantile ARO. Linkage analysis was performed to elucidate
the mutated gene (OSTM1, TCIRG1, and CLCN7) present in
our patient. The short tandem repeat markers in neigh-
boring OSTM1 and TCIRG1 did not show segregation with the
disease (Figure S1A and S1B) and were, therefore,
excluded. As shown in Figure S1C, consideration of D16S423
and D16S407, which were the nearest markers to the CLCN7
gene, showed that the haplotypes differed between sib-
lings. These markers presented segregation with the dis-
ease, revealing CLCN7 as the pathogenic gene in our
patient.
The CLCN7 gene from the patient was sequenced and
two mutations identified (Figure S2). The first mutation
was a G-to-A transition at nucleotide position 857 in exon
10 (c.857G>A, p.Arg286Gln) and was inherited from hisss of the bone marrow cavity in the long bones as shown in plain
metrical facial expression owing to right facial nerve palsy and
the insertion site of the ventriculoperitoneal shunt.
CLCN7 mutant in malignant osteopetrosis patient 157father. This missense mutation has been previously re-
ported.4 The other mutation, found in exon 14, was a
one-base deletion (c.1168delG) resulting in a trans-
lational frameshift from codon 390 and early termination
at codon 395 (p.Ala390LeufsTer6). This mutation was
inherited from his mother. The elder sister of the patient
was also a carrier of the c.1168delG mutation; a one-base
deletion mutation that has not yet been reported. This
result also corresponded to the linkage analysis. The
patient and his elder sister had the same haplotype
inherited from their mother, which was the allele car-
rying the mutation. Neither mutation was detected in 100
healthy volunteers enrolled in the control group. Soft-
ware packages used for the in silico analysis predicted
the pathogenicity of both CLCN7 mutations as follows:
PolyPhen2 (S24; likely damaging), Mutation Taster (S23;
disease causing), and SIFT (S25; damaging). Two addi-
tional single nucleotide polymorphisms, c.1170A>T
(p.Ala390Ala) and IVS13-42insC, were found, with both
sites linked to the c.1170T polymorphism.
Previously, the p.Arg286Gln mutation was reported in
a mild autosomal dominant osteopetrosis (ADO) patient,4
and a p.Arg286Trp mutation was found in a familial
benign ADO case.5 Here, we determined that although
the father of the patient carried one p.Arg286Gln muta-
tion, he remained asymptomatic. The amino acid
sequence alignment of seven human CLC chloride chan-
nels revealed that Arg286 is not a highly conserved res-
idue.5 We suspect that CLCN7 with an Arg286 mutation
would likely retain some of its original function and that
the phenotype associated with a single Arg286 mutation
would cause mild or no symptoms associated with ADO.
However, if another allele carried a more serious muta-
tion, such as a truncation mutation, the partial function
associated with an Arg286-mutated protein would
possibly be insufficient to meet physiological re-
quirements and would, therefore, present severe prob-
lems. It is likely that the Arg286 mutation would display
different influences on ADO and ARO.
There is currently no effective treatment for ARO,
especially for malignant infantile ARO. Many types of
treatment focus on supportive and symptomatic manage-
ment of complications.1 Bone-marrow transplantation
(BMT) is an important treatment method that should be
considered, but outcomes vary.6 Before our patient could
accept BMT, interferon gamma 1b (INFg1b) was adminis-
tered to improve his immune function. INFg1b was reported
to enhance bone resorption and increase bone marrow
space.7 Unfortunately, our patient expired at 4-years of age
due to sepsis and before any advanced treatment became
available.
4. Conclusion
This study extends the spectrum of CLCN7 mutations and
reveals that the combination of a p.Arg286Gln mutant alleleand an allele with a deletionmutation is capable of causing a
severe form of ARO. Additionally, CLCN7 gene profiling may
be useful in genetic counseling for families affected by ARO/
ADO. Finally, several gene mutations are associated with
osteopetrosis and linkage analysis could be used to narrow
down the number of genes submitted for sequencing anal-
ysis. However, next-generation sequencing technology con-
tinues to develop quickly and is now available in several
institutions. This new technology can be applied to analyze
multiple disease-causing genes simultaneously in order to
quickly reveal more detailed DNA variation information and
making it useful for the diagnosis of diseases caused by
multiple genes, such as osteopetrosis.
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